Clinical trials: Ophthalmic Solutions
Glaucoma, Angle-Closure
Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients
This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for…
- Trial name
- NCT01151904
- Testing
- brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution, latanoprost
- Where
- Thailand
- Volunteers
- 17 people
- Sponsor
- Allergan
Non-infectious Anterior Uveitis, Uveitic Glaucoma
TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
The primary objective of this study is to evaluate the efficacy and safety of TRS01 eye drops compared to active comparator in subjects with active non-infectious anterior uveitis with or without uveitic glaucoma
- Trial name
- NCT05042609
- Testing
- TRS01, FDA approved steroid eye drop (masked)
- Where
- 30 sites in United States, France and 1 more
- Volunteers
- 142 people
- Sponsor
- Tarsier Pharma
Macular Degeneration
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Part A (Phase IIa): Primary objectives: The study part A is designed to investigate whether the use of regorafenib eye drops can help patients with neovascular (wet) Age-Related Macular Degeneration (wAMD) to see better after 4…
- Trial name
- DREAM (NCT02222207)
- Testing
- Regorafenib, ophthalmic oily suspension (BAY73-4506), Ranibizumab
- Where
- 149 sites in United States, Australia and 16 more
- Volunteers
- 52 people
- Sponsor
- Bayer
Presbyopia, Refractive Errors
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
- Conditions
- Presbyopia, Refractive Errors, Eye Diseases
- Trial name
- NCT05294328
- Testing
- Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle Proprietary Ophthalmic Solution
- Where
- 5 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- LENZ Therapeutics, Inc
Allergic Conjunctivitis
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).
- Trial name
- NCT01119287
- Testing
- Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Alcon Research
Inflammation, Pseudophakia
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
This is a single-center, randomized, investigator-masked, parallel group, and active-comparator controlled study investigating the clinical outcomes for visual acuity and macular thickness after treatment with Bromday (bromfenac…
- Trial name
- NCT01310127
- Testing
- Bromfenac, Nepafenac
- Volunteers
- 23 people
- Sponsor
- Toyos Clinic
Dry Eye
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects…
- Trial name
- NCT03916042
- Testing
- Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Pterygium
Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24) Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)
- Trial name
- Pterygium (NCT03049852)
- Testing
- CBT-001 single dose, Vehicle, CBT-001 Multi-dose
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Cloudbreak Therapeutics, LLC
Refractive Error, Dry Eye
Determination of Cell Population in Solution-Induced Corneal Staining (SICS) and Symptomatic Versus Asymptomatic Lens Wearers
The purpose of the study is to investigate the corneal epithelial cell response associated with lens wear that results in solution-induced corneal staining (Phase1) and to determine the cell appearance in symptomatic and…
- Trial name
- ABBOTSFORD (NCT01629706)
- Testing
- Balafilcon A contact lens, Habitual contact lenses, Renu multi-purpose solution
- Volunteers
- 92 people
- Sponsor
- CIBA VISION
Glaucoma
Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®
Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic solution PRO-179 compared with Travatan®, on the ocular surface of clinically healthy subjects.
- Trial name
- PRO-179/I (NCT03965052)
- Testing
- PRO 179, Travatan 0.004 % Ophthalmic Solution
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Syndrome
Safety and Efficacy of BRM421 for Dry Eye Syndrome
The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT03066219
- Testing
- BRM421
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- BRIM Biotechnology Inc.
Allergic Conjunctivitis
A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial with Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic…
- Trial name
- NCT03660878
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Glaucoma, Open-Angle
H-1337 Ophthalmic Solution Phase 1/2
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with…
- Trial name
- NCT03452033
- Testing
- H-1337 [1], H-1337 [2], H-1337 [3]
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Allysta Pharmaceutical
Allergic Conjunctivitis
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT02322216
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle
- Volunteers
- 383 people
- Sponsor
- Alcon Research
Anesthesia, Local
A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution
A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution…
- Trial name
- NCT05501860
- Testing
- AG-920
- Where
- 2 sites in United States
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- American Genomics, LLC
Cataract Surgery
Efficacy and Safety of Bromfenac Ophthalmic Solution
This is a safety and efficacy study of bromfenac ophthalmic solution
- Trial name
- NCT00585975
- Testing
- bromfenac ophthalmic solution
- Where
- United States
- Volunteers
- 568 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT02978183
- Testing
- ST266, Saline (0.9% NaCl)
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Ocular Hypertension, Open Angle Glaucoma
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
- Trial name
- NCT02874846
- Testing
- Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Aerie Pharmaceuticals
Acute Bacterial Conjunctivitis
Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis
A Phase 2, Multi-center, Randomized, Parallel Controlled Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Ofloxacin Eye Drops in the Treatment of…
- Trial name
- NCT05816070
- Testing
- IVIEW-1201, Ofloxacin Eye Drops
- Where
- China
- Volunteers
- 129 people
- Sponsor
- IVIEW Therapeutics Inc.
Dry Eye
Clinical Evaluation of a Multidose Preservative-free Lubricating Eye Drops Contained in Novelia® Eye Dropper in Non-Contact Lens Wearing Patients
This is a 30-Day, multi-site, single-masked, bilateral, active- controlled, 2-Arm parallel group study to evaluate the safety and efficacy of an Investigational product.
- Trial name
- NCT05661851
- Testing
- Investigational Lubricating Eye Drop in a Novelia® bottle, Blink® Tears eye Drops
- Where
- 8 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.